Cardiovascular Medicine Use among Adults with ADHD: A Nationwide Study in Australia
Saved in:
| Title: | Cardiovascular Medicine Use among Adults with ADHD: A Nationwide Study in Australia |
|---|---|
| Language: | English |
| Authors: | Masako Araki (ORCID |
| Source: | Journal of Attention Disorders. 2026 30(6):773-783. |
| Availability: | SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: https://sagepub.com |
| Peer Reviewed: | Y |
| Page Count: | 11 |
| Publication Date: | 2026 |
| Document Type: | Journal Articles Reports - Research |
| Descriptors: | Heart Disorders, Adults, Attention Deficit Hyperactivity Disorder, Drug Therapy, Incidence, Gender Differences, Age Differences, Foreign Countries |
| Geographic Terms: | Australia |
| DOI: | 10.1177/10870547261418763 |
| ISSN: | 1087-0547 1557-1246 |
| Abstract: | Background: Despite cardiovascular conditions being common in adults with ADHD, data on patterns of cardiovascular medicine use in this population are scarce. Methods: Using dispensing claims for a 10% random sample of Australians, this population-based study comprised 14,753 adults with ADHD (defined as having ≥2 ADHD medicine dispensings in 2012-2020) who were 1:4 sex- and age-matched with 59,012 adults without ADHD (no ADHD dispensings). We estimated the prevalence of cardiovascular medicine use in 2021 among adults with and without ADHD, overall and by medicine type, sex, and age. Using Poisson regression, we calculated age- and sex-adjusted prevalence ratios (PRs) with 95% confidence intervals (CIs) to assess associations. Results: Overall cardiovascular medicine use was more prevalent among adults with ADHD than those without (16.5% vs. 10.0%, aPR=1.7, 95% CI [1.6, 1.7]), with the highest difference among those aged 18 to 29 years (aPR=2.8, 95% CI [2.4, 3.1]). We observed increased differences in use of propranolol (3.2% vs. 0.7%), loop diuretics (0.8% vs. 0.4%), potassium-sparing diuretics (0.9% vs. 0.4%), cardiac therapy (0.8% vs. 0.5%), and antithrombotic agents (2.2% vs. 1.4%). Among females, we noted associations of ADHD with specific diuretic subgroups (loop, aPR=2.8, 95% CI [2.1, 3.7]; potassium-sparing, aPR=2.5, 95% CI [1.9, 3.3]). Conclusion: We identified an elevated prevalence of cardiovascular medicine use among adults with ADHD, particularly among younger people. We also observed distinct patterns in specific medicine use between sexes, suggesting potential sex-specific effect modification. Our findings underscore the importance of regular monitoring and management of cardiovascular health among people with ADHD across the lifespan. |
| Abstractor: | As Provided |
| Entry Date: | 2026 |
| Accession Number: | EJ1504205 |
| Database: | ERIC |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Despite cardiovascular conditions being common in adults with ADHD, data on patterns of cardiovascular medicine use in this population are scarce. Methods: Using dispensing claims for a 10% random sample of Australians, this population-based study comprised 14,753 adults with ADHD (defined as having ≥2 ADHD medicine dispensings in 2012-2020) who were 1:4 sex- and age-matched with 59,012 adults without ADHD (no ADHD dispensings). We estimated the prevalence of cardiovascular medicine use in 2021 among adults with and without ADHD, overall and by medicine type, sex, and age. Using Poisson regression, we calculated age- and sex-adjusted prevalence ratios (PRs) with 95% confidence intervals (CIs) to assess associations. Results: Overall cardiovascular medicine use was more prevalent among adults with ADHD than those without (16.5% vs. 10.0%, aPR=1.7, 95% CI [1.6, 1.7]), with the highest difference among those aged 18 to 29 years (aPR=2.8, 95% CI [2.4, 3.1]). We observed increased differences in use of propranolol (3.2% vs. 0.7%), loop diuretics (0.8% vs. 0.4%), potassium-sparing diuretics (0.9% vs. 0.4%), cardiac therapy (0.8% vs. 0.5%), and antithrombotic agents (2.2% vs. 1.4%). Among females, we noted associations of ADHD with specific diuretic subgroups (loop, aPR=2.8, 95% CI [2.1, 3.7]; potassium-sparing, aPR=2.5, 95% CI [1.9, 3.3]). Conclusion: We identified an elevated prevalence of cardiovascular medicine use among adults with ADHD, particularly among younger people. We also observed distinct patterns in specific medicine use between sexes, suggesting potential sex-specific effect modification. Our findings underscore the importance of regular monitoring and management of cardiovascular health among people with ADHD across the lifespan. |
|---|---|
| ISSN: | 1087-0547 1557-1246 |
| DOI: | 10.1177/10870547261418763 |
